Table 1 The main characteristics of the eligible studies
From: Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis
Study (Author and year) | Country | size | Tumor type | Sample type | Method (antibody data) | Negative control | Expression location | Cut-off value: (intention) or (IPS = x * y) | High expression ratio: n/N (%) | Follow-up time: mean (min–max) (mon) | Survival outcome | Conclusion (UA/MA) | Multivariate analysis | HR extraction | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yoshida et al. 2017 (I) [14] | Japan | 79 | PDAC | ac (Ca) Startle (St) | IHC (M, Merck Millipore) | NT + NP | NR | 50% | Ca: 54/79 (68%) St: 49/79 (62%) | NR | OS; RFS OS; RFS | NS; NS; NS; P | No | KM plot | 8 |
Zhan et al. 2015 [15] | China | 31 | PDAC | ac | IHC (Millipore) | PBS | NR | 50% | 15/31 (48%) | 47 (3–73) | OS | P | No | P-value | 7 |
Mahawithitwong et al. 2013 [16] | Japan | 95 | PDAC | sf | IHC (R, Protein TechGroup, 1:100) | NR | NR | (4 * 3) 4/12 | 34/95 (64.2%) | 24 (3–136); 14 (0–136) | OS; DFS | P/NS; P/− | Yes | Cox, P-value | 7 |
Cao et al. 2015 (II) [17] | China | 110 | ESCC | scc | IHC (M, Origen,1:50) | NR | C + N | (3 * 4) NR | 34/65 (52%) | 36.5 (0–148.7) | OS; DFS | −/P; −/P | Yes | Cox | 6 |
Cao et al. 2015 (III) [17] | China | 147 | ESCC | scc | IHC (M, Origen,1:50) | NR | C + N | (3 * 4) NR | 20/64 (31%) | 28.8 (27–72) | OS; DFS | P; P | Yes | Cox | 6 |
Wu et al. 2017 [18] | China | 203 | BC | sf | IHC (M, Santa Cruz, 1:500) | PBS | NR | (3 * 4) 6/12 | 109/203 (54%) | 64 (49–78) | OS; CSS; DFS | P/P; P/−; P/− | Yes | Cox | 6 |
Papachristou et al. 2008 [19] | Greece etc. | 60 | CHS | sf | IHC (M, homemade, 1/50) | TBS | C | 33% | 51/60 (85%) | 67.9 (40.9, 2–180) | OS | P | No | P-value | 8 |
Ge et al. 2015 [20] | China | 72 | HCC | ac | IHC (R, ab152106, 1:100) | PBS | NR | (4 * 3) 4/12 | 43/72 (60%) | NR (17.96–43.11) | OS; DFS | P/P; P/P | Yes | Cox | 7 |
Lin et al. 2017 [21] | China | 127 | HCC | ac | IHC (M, MAB2617, Billerica, 1:100) | NR | C | (3 * 4) 4/12 | 103/127 (81%) | 22 (1–94) | OS | P/P | Yes | Cox | 8 |
Ning et al. 2017 [22] | China | 100 | OSS | Sarcoma | IHC (R, Millipore, 1:150) | PBS | N | (3 * 4) 4.56/12 | 51/100 (51%) | 29.82 (5.26–38.89) | OS; DFS | P/P; P/P | Yes | Cox | 7 |
Ou et al. 2016 [23] | China | 188 | Glioma | Carcinoma | IHC (1:100) | NR | NR | 4/12 | 132/188 (70%) | NR (0–39) | OS | P/P | Yes | Cox | 8 |
Ren et al. 2014 [24] | China | 113 | sEOC | scc | IHC (R, Dako, 1:2000) | PBS | NR | (4 * 4) 12/16 | 91/113 (80%) | NR | OS; PFS | N/NS; N/N | Yes | KM-plot | 6 |
Shen et al. 2012 [25] | China | 40 | GC | ac | WB (R, ab74030, Abcam, 1:600) | actin | NR | Ratio: K2/actin > 2 | 22/40 (55%) | 37.1 (5–77) | OS; PFS | P/NS; P/P | Yes | Cox | 8 |
Li et al. 2017 [26] | China | 109 | ccRCC | ac | IHC (M, Millipore) | NT | C | 50% | 70/109 (64%) | 69 (0.94–82) | OS | P/NS | Yes | Cox | 7 |
Yan et al. 2016 [27] | China | 336 | ccRCC | ac | IHC (M, ab117962, Abcam, 1:100) | NR | NR | (3 * 3) 4/9 | 199/336 (59%) | NR (10–60) | OS; DFS | −/P; −/P | Yes | Cox | 7 |